TFF3 modulates NF-{kappa}B and a novel negative regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}

Ya-Qin Zhu1,2 and Xiao-Di Tan1,2

1Molecular and Cellular Pathobiology Program, Children’s Memorial Research Center, Children’s Memorial Hospital, Chicago; and 2Departments of Pathology and Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

Submitted 19 April 2005 ; accepted in final form 6 July 2005


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Trefoil factor 3 (intestinal trefoil factor) is a cytoprotective factor in the gut. Herein we compared the effect of trefoil factor 3 with tumor necrosis factor-{alpha} on 1) activation of NF-{kappa}B in intestinal epithelial cells; 2) expression of Twist protein (a molecule essential for downregulation of nuclear factor-{kappa}B activity in vivo); and 3) production of interleukin-8. We showed that Twist protein is constitutively expressed in intestinal epithelial cells. Tumor necrosis factor-{alpha} induced persistent degradation of Twist protein in intestinal epithelial cells via a signaling pathway linked to proteasome, which was associated with prolonged activation of NF-{kappa}B. In contrast to tumor necrosis factor, trefoil factor 3 triggered transient activation of NF-{kappa}B and prolonged upregulation of Twist protein in intestinal epithelial cells via an ERK kinase-mediated pathway. Unlike tumor necrosis factor-{alpha}, transient activation of NF-{kappa}B by trefoil factor 3 is not associated with induction of IL-8 in cells. To examine the role of Twist protein in intestinal epithelial cells, we silenced the Twist expression by siRNA. Our data showed that trefoil factor 3 induced interleukin-8 production after silencing Twist in intestinal epithelial cells. Together, these observations indicated that 1) trefoil factor 3 triggers a diverse signal from tumor necrosis factor-{alpha} on the activation of NF-{kappa}B and its associated molecules in intestinal epithelial cells; and 2) trefoil factor 3-induced Twist protein plays an important role in the modulation of inflammatory cytokine production in intestinal epithelial cells.

trefoil factor 3; signal transduction


THE TRANSCRIPTION FACTOR NF-{kappa}B is involved in important biological processes, including inflammation and apoptosis (23, 55). Many extracellular stimuli induce NF-{kappa}B activation. The physiological roles of NF-{kappa}B are both cell type and stimulus dependent (23, 55). Previous investigations have shown that activation of NF-{kappa}B by extracellular stimuli such as tumor necrosis factor-{alpha} (TNF) is predominantly mediated by a distinctive signaling pathway linked to degradation of I{kappa}B{alpha}. Activated NF-{kappa}B complex is translocated into the nucleus and binds to the promoter regions of its targeted genes (23).

Recent studies have suggested the existence of autoregulatory loops for a net negative regulation of NF-{kappa}B functions in mammalian cells (3, 4, 6, 10, 38, 43, 44). For example, activation of NF-{kappa}B results not only in upregulation of genes involved in inflammation and cell survival but also in synthesizing/resynthesizing NF-{kappa}B-dependent negative regulators of NF-{kappa}B signaling, such as I{kappa}B{alpha}, Bcl-3, A20, nitric oxide, and prostaglandin E2 (6, 10, 25, 26, 29, 39, 43, 44). Newly synthesized I{kappa}B{alpha} and Bcl-3 are translocated into the nucleus and serve to terminate NF-{kappa}B action (3, 6), whereas A20, nitric oxide, and prostaglandin E2 are responsible for blocking the NF-{kappa}B pathway (12, 13, 28). Overexpression of I{kappa}B{alpha} results in cardioprotection in trauma (7). Mice lacking A20 suffer from severe systemic inflammation (28, 43). Taken together, the negative regulatory loop of NF-{kappa}B ensures transient generation of intracellular signaling to prevent uncontrolled NF-{kappa}B activation. It is critical to limit inflammatory injury by terminating and blocking proinflammatory cytokine-induced NF-{kappa}B activity in vivo.

Twist protein is a basic helix-loop-helix transcription factor. In mammals, Twist contributes to the morphogenesis of cranial neural tube and participates in the regulation of muscular differentiation (9). Previously, Sosic et al. (43) have demonstrated that 1) Twist protein interacts with transcription factor NF-{kappa}B; 2) Twist is essential for the downregulation of NF-{kappa}B activity in vivo; and 3) NF-{kappa}B regulates Twist gene expression. Thus Twist protein is a NF-{kappa}B-associated protein. It plays an important role in the regulation of the negative regulatory loop of NF-{kappa}B pathway and the attenuation of inflammatory responses (42). Recently, Twist has been shown to be present in mouse mammary epithelial cell lines (18), suggesting that it may be involved in the regulation of physiological or pathophysiological processes in epithelial tissues.

The trefoil factor (TFF) family is a group of extracellular peptides that were originally found in the gastrointestinal (GI) tract (37, 51, 53). These peptides contain distinctive cystine-rich "trefoil" domains and are resistant to proteolytic degradation (16, 37, 51). Three mammalian TFFs have been identified, namely, pS2 (TFF1), SP (TFF2), and intestinal trefoil factor (ITF or TFF3). TFFs are expressed in several tissues of the body but are most pronounced in the GI tract. They are usually associated with the mucous layer in the GI tract. Under normal circumstances, TFF1 and TFF2 are expressed in the human stomach, whereas TFF3 is expressed in the small and large intestines. The expression of TFF has been demonstrated to be upregulated in GI tract ulcers (2). In contrast to TGF-{alpha} and EGF, TFFs are expressed rapidly in response to injury. It has been shown that intestinal epithelium is the targeted tissue of TFFs (17).

TFF3 is predominantly expressed in mucous epithelia. A major source for TFF3 is goblet cells of the small and large intestine. Maximal TFF3 expression in the GI tract was observed in the distal portions of the ileum and the colon (31). Secretion of TFF3 is evoked by certain neurotransmitters and inflammatory mediators (33). Among TFFs, the physiological functions of TFF3 have been well characterized. Previous studies (35) demonstrated that TFF3 enhances restitution in intestinal epithelial cells and sustains mucosa integrity. We showed that TFF3 protects epithelial cells against reactive oxygen species-induced injury (45). In addition, we found that TFF3 also induces activation of NF-{kappa}B in intestinal epithelial cells and demonstrated that TFF3 prevents apoptosis of intestinal epithelial cells via NF-{kappa}B pathway (8). Pretreatment of the GI mucosa with TFF3 protects epithelium against various injuries (5, 24, 45). However, it is still unknown whether TFF3 modulates inflammatory responses in intestinal epithelial cells. In the present study, we examined 1) how TFF3 activates NF-{kappa}B in intestinal epithelial cells, 2) whether Twist protein is expressed in intestinal epithelial cells and regulated by TFF3 and TNF, and 3) whether Twist protein plays a role in modulation of expression of NF-{kappa}B-targeted proinflammatory cytokines, such as IL-8 in intestinal epithelial cells.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Reagents. All cell culture media were obtained from GIBCO Invitrogen (Carlsbad, CA). Polyclonal antibodies against Twist (SC-15393), I{kappa}B{alpha} (SC-371), p50 (SC-114X), and p65 (SC-109X) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phosphotyrosine MAb (clone 4G10) was purchased from Upstate Biotechnology (Lake Placid, NY). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (catalog no. 111-035-144) and anti-mouse IgG (catalog no. 115-035-062) were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA). MAb against GAPDH was purchased from Abcam (Cambridge, MA). Chemicals and molecular biology reagents were purchased from Sigma (St. Louis, MO). Reagents for electrophoresis and Western blotting were supplied by Bio-Rad Laboratories (Hercules, CA). Precasted 4–20% iGels were purchased from Gradipore (Frenchs Forest, Australia). Quanti Kine Human IL-8 Immunoassay Kit was purchased from R & D Systems (Minneapolis, MN). Protease inhibitor cocktail tablets were supplied by Roche Molecular Biochemicals (Indianapolis, IN). All tissue culture plastic ware was supplied by Costar (Cambridge, MA). U0126 and PD-98059 (selective inhibitors for ERK kinase) and MG132 (a potent proteasome inhibitor) were obtained from Biomol (Plymouth Meeting, PA). Enhanced chemiluminescence (ECL) system and [{gamma}-32P]ATP were supplied by Amersham Pharmacia Biotech (Piscataway, NJ).

Preparation of rat recombinant TFF3 in yeast. Rat TFF3 was expressed from Pichia pastoris using a method modified from our previous protocol (8). The recombinant protein was purified with a fast-performance liquid chromatography (AKTA FPLC, Amersham Pharmacia Biotech). The purified TFF3 peptide was visualized as a single band with the silver staining technique. Its biological activity was assessed by the cell migration assay using IEC-18 cells. The peptide induced an approximately threefold increase in cell migration.

Cell culture. HT-29 and IEC-18 cells were purchased from American Type Culture Collection (Rockville, MD) and cultured in a water-saturated atmosphere with 5% CO2 at 37°C. HT-29 cells (passages 2035 after receipt from American Type Culture Collection) were maintained in Dulbecco’s modified Eagle’s minimum essential medium containing 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% heat-inactivated FBS. IEC-18 cells were maintained in Dulbecco’s modified Eagle’s minimum essential medium supplemented with 10% heat-inactivated FBS, insulin (0.1 U/ml), 1% nonessential amino acids, 100 U/ml penicillin, and 100 µg/ml streptomycin.

Western blot analysis. Cells were lysed in a buffer containing 2 mM Tris-Cl (pH 7.6), 30 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, complete protease inhibitor cocktail (1 tablet/10 ml), and 1% Nonidet P-40. Total cell lysate was processed through sonication at 4°C and followed by centrifugation at 10,000 g for 10 min at 4°C. Supernatants were mixed with an equal volume of 2x Laemmli buffer and boiled for 5 min. Thirty micrograms of protein were resolved on 4–20% SDS-PAGE gel along with molecular weight standards. The proteins were then transferred onto a nitrocellulose membrane as described before (57). The membranes containing sample proteins were used for immunodetection of Twist protein. Briefly, blots preincubated with PBS containing 5% skim milk were reacted with primary antibody against Twist protein (1:500) for 1 h at room temperature. After incubation, the blot was washed four times with PBS containing 0.05% Tween 20 (PBST), and then incubated with PBST containing 1:10,000 diluted HRP-conjugated goat anti-rabbit IgG for 1 h at room temperature. After additional washing with PBST, immune complexes on the blot were visualized using the ECL system. Blots were stripped and reprobed with MAb against GAPDH (1:10,000) following a standard procedure (45).

Immunoprecipitation. Lysate containing 0.4 mg of proteins was treated with 1 µg of rabbit anti-I{kappa}B{alpha} antibodies in 800 µl of lysate buffer at 4°C overnight, and the immune complexes were precipitated with protein A/G-Sepharose beads. The beads were thoroughly washed, resuspended in SDS sample buffer, and boiled for 5 min. After being boiled, the proteins were resolved on 4–20% SDS-PAGE gel, electrotransferred to a nitrocellulose membrane, and probed with mouse anti-phosphotyrosine monoclonal antibody (1:1,000). The blot was then treated with HRP-conjugated goat anti-mouse IgG and finally detected using ECL reagent.

Preparation of nuclear extracts from cells. After the medium was removed, cells (5 x 106) were washed with cold PBS containing 0.5 mM DTT, directly treated with 500 µl of buffer A containing 10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.1% Nonidet P-40, scraped off petri dishes, and incubated for 15 min at 4°C. The nuclei were collected by a brief centrifugation using a microcentrifuge (8). The supernatant was removed. The nuclear pellet was washed with buffer A and resuspended in 150 µl of buffer B containing 20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.5 mM DTT, 0.42 M NaCl, 0.2 mM EDTA, 25% glycerol, and 0.5 mM PMSF, and then incubated for 15 min on ice. Following a 10-min centrifugation at 14,000 g at 4°C, the supernatant (nuclear protein fraction) was diluted in buffer C containing (in mM) 20 HEPES, pH 7.9, 50 KCl, 0.5 DTT, 0.2 EDTA, 0.5 PMSF to 300 µl (5 x 106 cells), and stored at –80°C. Protein concentration was measured using Bradford method.

EMSA and supershift assay. NF-{kappa}B DNA-binding activity was determined by EMSA as described before (8). Briefly, the NF-{kappa}B consensus oligonucleotide was labeled by [{gamma}-32P]ATP (3,000 Ci/mmmol, 10 mCi/ml) with T4 polynucleotide kinase. Nuclear extracts (5 µg) were added to 10 µl of gel shift binding buffer [40% glycerol, 10 mM Tris·HCl, pH 7.5, 50 mM NaCl, 0.5 mM EDTA, 1 mM MgCl2, 0.5 mM DTT, 0.01 mg/ml poly(dI-dC)]. 32P-Labeled oligonucleotide probe (1 µl) was added and the mixture was incubated at room temperature for 20 min. Electrophoresis was done on a 6% polyacrylamide gel with 0.5x Tris-borate-EDTA buffer. The gel was dried and analyzed using a phosphorimaging system. Supershift experiments were performed as follows. Nuclear extracts were incubated with 32P-labeled oligonucleotide (1 µl) at room temperature for 20 min. Antibody (1 µg) against p50, p65, p52, c-Rel, or RelB subunit of NF-{kappa}B was subsequently added, samples were incubated at room temperature for 15 min, and electrophoresis was performed. To confirm the specificity of NF-{kappa}B DNA binding activity, a competitive experiment was done by adding 1 µl (1,750 pmol/ml) of unlabeled oligonucleotide to the reaction mixture.

ELISA assay for quantitation IL-8 in conditioned medium. Cells were harvested by trypsinization and seeded at 5 x 104 cells/well in 96-well tissue culture plates. Cells were further incubated for 2 days to reach confluence. The medium of confluent monolayers was changed to serum-deprived medium, and cells were cultured overnight. The medium was then changed to fresh serum-deprived medium containing different stimulators and incubated for the indicated times. Medium was collected and IL-8 was detected using Quantikine human IL-8 immunoassay kit (R & D Systems). The protocol provided by the manufacturer was followed. Standard curves were generated for IL-8 using the standard provided in the kit, and the concentration of IL-8 in the cell supernatant was determined by interpreting from the appropriate standard curve.

Immunohistochemical staining. Rat intestinal tissues were sectioned with a cryostat system, fixed with acetone for 10 min at –20°C, and air dried. Slides were rinsed with PBS and incubated with PBS containing 1% BSA for 10 min. Next, slides were incubated with rabbit polyclonal antibody (PAb) against Twist (1:500) for 30 min, washed, and incubated with biotinylated goat anti-rabbit IgG for 30 min. After being washed, slides were incubated with FITC-labeled streptavidin for 30 min, washed, and covered with FluorSave reagent (Calbiochem, San Diego, CA). The staining was performed at room temperature. Finally, slides were visualized under a fluorescence microscope.

siRNA-mediated Twist gene silencing. The siRNA duplexes targeting the human Twist mRNA (GenBank accession no. NM_000474) were designed with the most efficient siRNA-2 duplex design protocol and synthesized by Qiagen (Valencia, CA). The targeting sequences of double-stranded siRNA are TGG GAT CAA ACT GGC CTG CAA and TAA GAA CAC CTT TAG AAA TAA. These sequences were submitted to a Basic Local Alignment Search Tool to ensure that only the TWIST gene was targeted by the TWIST siRNA, and control sequences (nonsilencing labeled control siRNA) were not homologous to any known genes. HT-29 cells were transfected using RNAi Human/Mouse Control kit (Qiagen). In brief, HT-29 cells were seeded onto six-well plates (4 x 104 cells/well) 24 h before siRNA treatment. For transfection, siRNA (1.9 µg/ml) was transfected with the RNAiFect reagent (Qiagen), according to the manufacturer’s instructions. Twenty-four hours after transfection, culture medium was changed. Cells were used for designed experiments on the fourth day after transfection.

Statistics. Data were expressed as means ± SE, ANOVA and one-way ANOVA, followed by Fisher’s protected least-significant differences post hoc test to assess the significance of differences. P < 0.05 was considered significant.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
In the present study, we used intestinal epithelial cell lines, including HT-29 and IEC-18 lines. The cell lines for studying the mechanisms of TFF3 action in intestinal epithelia are selected based on the following rationales. First, epithelial cell lines from both small and large intestines are selected because TFF3 is expressed in both. Second, the cell lines selected are well characterized, consist of a homogeneous cell population, and are easily maintained in culture. Third, the cells to be used should express many characteristics of the normal intestinal epithelium. Finally, the cells to be used should respond to rat TFF3 stimulation in vitro. IEC-18 is a nontransformed rat small intestinal epithelial cell line derived from undifferentiated crypt epithelial cells. HT-29 cell line originates from human colon carcinomas and shows many characteristic features of intestinal epithelium. Both IEC-18 and HT-29 cell lines have previously been used for TFF3 study by various investigators and respond to rat TFF3 stimulation (24, 36, 47). Therefore, we selected them for our studies.

TFF3 activates NF-{kappa}B in intestinal epithelial cells in a manner different from TNF. Our recent investigation suggests that TFF3 activates NF-{kappa}B in intestinal epithelial cells (8). Here, we further examined the kinetics of TFF3-induced NF-{kappa}B activation. HT-29 cells were treated with TFF3 (2.5 µM) for 0.5, 1, 2, 4, 8, and 24 h respectively. At the end of the treatment, nuclear proteins were extracted and an EMSA was performed with 32P-labeled NF-{kappa}B consensus probe. As shown in Fig. 1A, a low basal level of NF-{kappa}B activity was detected in resting HT-29 cells. NF-{kappa}B binding activity was induced within 30 min after treatment and rapidly fell thereafter, reaching control levels by 60 min. The specificity of DNA/NF-{kappa}B binding was confirmed with a 100-fold excess of unlabeled NF-{kappa}B consensus oligonucleotide (data not shown). Incubation of nuclear extracts with anti-p65 antibody resulted in the abrogation in NF-{kappa}B/DNA complex, whereas anti-p50 antibody had no effect (Fig. 1A). In addition, the NF-{kappa}B/DNA complex was not reduced by antibodies against p52, c-Rel, or RelB (data not shown). Together, the data suggests that NF-{kappa}B activated by TFF3 in human intestinal epithelial cells was composed of p65 homodimer. In contrast, TNF induced strong NF-{kappa}B activation in HT-29 cells, and the effect persisted for 24 h (Fig. 1B). Supershift assay revealed that TNF-activated NF-{kappa}B in intestinal epithelial cells contained p50/p65 heterodimers (Fig. 1B).



View larger version (57K):
[in this window]
[in a new window]
 
Fig. 1. Effect of trefoil factor 3 (TFF3) and TNF on activation of NF-{kappa}B in human intestinal epithelial cells (IECs). A: time course of TFF3 effect on activation of NF-{kappa}B in human IECs. Nuclear extracts from HT-29 cells either unstimulated or stimulated for indicated times with TFF3 (2.5 µM) were subjected to EMSA/supershift assay, as described in MATERIALS AND METHODS. Data are representative of 3 separate experiments. B: time course of TNF effect on activation of NF-{kappa}B in human IECs. Nuclear extracts from HT-29 cells either unstimulated or stimulated for indicated times with TNF (10 ng/ml) were subjected to EMSA/supershift assay, as described in MATERIALS AND METHODS. Data are representative of 3 separate experiments.

 
Extracellular stimulus activates NF-{kappa}B mainly through inducing either rapid degradation of I{kappa}B{alpha} protein following phosphorylation of Ser32 and Ser36 of I{kappa}B{alpha} by I{kappa}B kinase or tyrosine phosphorylation of I{kappa}B{alpha} protein without proteolytic degradation of I{kappa}B{alpha} (21, 23). To dissect the process through which TFF3 activates NF-{kappa}B in intestinal epithelium, we investigated whether TFF3 induces degradation of I{kappa}B{alpha}. For this, HT-29 cells were subjected to treatment with TFF3 (2.5 µM), total cellular proteins were isolated, and Western blot analysis was performed with rabbit anti-I{kappa}B{alpha} polyclonal antibody. Strikingly, treatment of HT-29 cells with TFF3 resulted in partial degradation of I{kappa}B{alpha} within 30 min. I{kappa}B{alpha} was actively resynthesized 2 h after the treatment and increased thereafter (Fig. 2A). The data suggested phosphorylation of Ser32 and Ser36 of I{kappa}B{alpha} after TFF3 stimulation. To further explore whether TFF3 also induces tyrosine phosphorylation of I{kappa}B{alpha} protein, whole cell lysates from untreated and TFF3-treated HT-29 cells were immunoprecipitated either with preimmune sera or with anti-I{kappa}B{alpha} antibody, followed by Western blot analysis with anti-phosphotyrosine antibody. In the positive control, we subjected cells to treatment with pervanadate (100 µM) for 30 min, lysate, immunoprecipitation, and Western blot analysis. As shown in Fig. 2B, I{kappa}B{alpha} immunoprecipitated from pervanadate-treated cells was tyrosine phosphorylated. In contrast, tyrosine-phosphorylated I{kappa}B{alpha} was not detected in TFF3-treated cells.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2. Effect of TFF3 on modulation of I{kappa}B{alpha} in IECs. A: stimulation with TFF3 results in partial degradation of I{kappa}B{alpha}. Cell lysates (30 µg) from HT-29 cells either unstimulated or stimulated for indicated times were subjected to SDS-PAGE and transferred to membranes. The membranes were subjected to Western blot (WB) analysis with anti-I{kappa}B{alpha} polyclonal antibody (PAb), as described in MATERIALS AND METHODS. Top, representative autoradiographs of an immunoblot. Bottom, densitometric analysis of immunoblot data. *P < 0.05 vs. 0 h. Data are expressed as means ± SE of 3 determinations. B: stimulation with TFF3 does not result in tyrosine phosphorylation of I{kappa}B{alpha}. Cell lysates (400 µg) from HT-29 cells either unstimulated or stimulated for indicated times with 2.5 µM TFF3 were processed for immunoprecipitation with anti-I{kappa}B{alpha} antibody. Resulting immunocomplexes were subjected to SDS-PAGE and transferred to membranes. The membranes were subjected to Western blot analysis using anti-PY MAb, as described in MATERIALS AND METHODS. Data are representative of 3 separate experiments. Van, pervanadate; IP, immunoprecipitate.

 
To compare the effect of TFF3 and TNF on the degradation of I{kappa}B{alpha}, HT-29 cells were also treated cells with TNF, followed by detection of I{kappa}B{alpha} protein using Western blot analysis. We confirmed that I{kappa}B{alpha} protein was extensively degraded 30 min after TNF administration and subsequently resynthesized (data not shown). Together, the data suggest that TFF3 induces partial degradation of I{kappa}B{alpha} but without induction of its tyrosine phosphorylation in intestinal epithelial cells. The effect is associated with transient activation of p65/p65 homodimer NF-{kappa}B. In contrast to TFF3, TNF induced more degradation of I{kappa}B{alpha} and prolonged activation of p50/p65 heterodimer NF-{kappa}B in intestinal epithelial cells.

TFF3 does not induce IL-8 production in intestinal epithelial cells. Persistent activation of NF-{kappa}B in intestinal epithelial cells results in upregulation of several NF-{kappa}B-targeted proinflammatory cytokines such as IL-8. However, whether transient activation of NF-{kappa}B induces inflammatory mediators is not clear. Because we have shown that TFF3 induces transient activation of NF-{kappa}B in intestinal epithelial cells, we further examined the ability of TFF3 to induce the release of IL-8 by intestinal epithelial cells. For this experiment, we subjected HT-29 cells to stimulation with TFF3 (2.5 µM) or TNF (10 ng/ml) for 1 h. We then removed the medium, washed the cells with PBS, added fresh standard medium, and chased for 23 h. Thereafter, we measured IL-8 in culture medium using ELISA. As shown in Fig. 3, TNF strongly induced IL-8 release in HT-29 cells, whereas TFF-3 showed no effect. The data indicated that transient activation of NF-{kappa}B by TFF3 did not result in IL-8 production in intestinal epithelial cells.



View larger version (10K):
[in this window]
[in a new window]
 
Fig. 3. Modulation of IL-8 production by TNF and TFF3 in IECs. HT-29 cells were treated with TNF (10 ng/ml) and TFF3 (2.5 µM) for 24 h, respectively. Conditioned medium from untreated or treated cells were subjected to measurement of IL-8 with ELISA assay, as described in MATERIALS AND METHODS. Results are the means ± SE of 3 independent experiments. **P < 0.01, significantly different from control.

 
Twist is constitutively expressed in intestinal epithelial cells. Twist plays an important role in the attenuation of inflammation in multiple tissues such as muscles and skin (43). It blocks NF-{kappa}B-regulated gene expression (43). To determine whether intestinal epithelium expresses Twist, total cellular protein extracted from intestinal epithelial cells, including HT-29 and IEC-18 cell lines, were used for Western blot analysis. Rat skeletal muscle tissue was used as the positive control. As shown in Fig. 4A, Twist protein was present in both HT-29 and IEC-18 cells. Furthermore, the localization of Twist protein in rat small intestinal tissue was visualized using immunofluorescence microscopy with anti-Twist polyclonal antibody. As shown in Fig. 4B, cytosol of intestinal epithelial cells and some cells in the lamina propria stained with anti-Twist PAb. In contrast, intestinal epithelium did not stain with control preimmune serum (Fig. 4C). The data suggest that Twist protein is present in intestinal epithelial cells in vivo.



View larger version (68K):
[in this window]
[in a new window]
 
Fig. 4. Expression of Twist in intestinal epithelium. A: Twist is constitutively expressed in IECs in vitro. Total cellular proteins were isolated from rat hindlimb muscles, IEC-18, and HT-29 cells, respectively. Thirty micrograms of protein were subjected to SDS-PAGE, transferred to membranes, and analyzed using Western blot analysis with anti-Twist Ab (1:500 dilution). B and C: localization of Twist protein in the rat small intestinal tissue. Cryostat sections from the small intestine of a normal rat were stained with immunofluorescence using antibody against Twist (B) or rabbit preimmune serum (C). Sections were observed using immunofluorescence microscopy. Original magnification, x100.

 
Effect of TNF on expression of Twist protein in intestinal epithelial cells. Recently, Sosic et al. (43) demonstrated that Twist plays an important role in the attenuation of inflammation in multiple tissues such as muscles and skin. To investigate whether inflammatory mediators such as TNF modulate the expression of Twist in intestinal epithelial cells, HT-29 cells were stimulated with TNF (10 ng/ml) for up to 24 h. Cells were then lysed and processed for Western blot analysis. Time course analysis revealed that levels of Twist protein in HT-29 cells dropped within 30 min of treatment with TNF and persisted at low levels for up to 24 h (Fig. 5A). Under similar conditions, TNF also induced a decrease of Twist protein in IEC-18 cells (Fig. 5B). These data suggests that TNF induces the degradation of Twist in intestinal epithelial cells.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5. Time course of downregulation of Twist protein in IECs by treatment with TNF. HT-29 (A) and IEC-18 (B) cells were subjected to stimulation with TNF (10 ng/ml) for different time points and lysis thereafter. Total protein lysates (30 µg) were subjected to SDS-PAGE and transferred to membranes. The blots were subjected to Western blot analysis using anti-Twist Ab. The membranes were stripped and immunoblotted with anti-GAPDH MAb (housekeeping gene). Twist protein expression at each time point was normalized to that of GAPDH expression by using densitometry. Normalized content was compared with that at time 0. Top, representative autoradiographs of an immunoblot. Bottom, densitometric analysis of immunoblot data. **P < 0.005 vs. 0 h. ***P < 0.001 vs. 0 h. Data are means ± SE of 3 determinations.

 
Previous studies (19, 20) have shown that modulation of various signaling proteins by TNF requires 26S proteasome. To investigate whether proteasome plays a role in TNF-induced degradation of Twist, HT-29 cells were pretreated with MG132 (50 µM, a selective proteasome inhibitor) for 60 min, followed by stimulation with TNF for 30 min. As shown in Fig. 6, pretreatment of cells with MG132 resulted in blocking the effect of TNF on the expression of Twist protein. Epoxomicin (32), another selective proteasome inhibitor, also blocked the TNF effect. This result suggests that TNF-triggered degradation of Twist in intestinal epithelial cells is mediated by proteasome.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6. Role of proteasome on TNF-induced degradation of Twist protein in IECs. Selective proteasome inhibitors block the effect of TNF on reduction of Twist protein in IECs. Cell lysates (30 µg) from HT-29 cells untreated or treated with indicated stimulators were subjected to SDS-PAGE and transferred to membranes. The membranes were subjected to Western blot and densitometric analysis as in Fig. 5. Results are the means ± SE of 3 independent experiments. *P < 0.05, significantly different from control. MG132 (MG, 50 µM) and epoxomicin (Epx, 100 nM) are selective proteasome inhibitors.

 
Effect of TFF3 on expression of Twist protein in intestinal epithelial cells. TFF3 is an important GI peptide. It protects intestinal epithelial cells against injuries (35). Previous investigations have demonstrated that TFF3 is upregulated in intestinal inflammatory conditions such as inflammatory bowel disease (2). However, the role of TFF3 in inflammation remains unclear. We first investigated whether TFF3 regulates Twist expression. We treated intestinal epithelial cells with TFF3 (2.5 µM) at different time points and isolated total cellular protein for Western blot analysis. As shown in Fig. 7, treatment with TFF3 resulted in upregulation of Twist protein in HT-29 cells within 30 min. The effect persisted for 24 h after the treatment.



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 7. Effect of TFF3 on the expression of Twist protein in IECs. Top, representative autoradiographs of an immunoblot. Bottom, densitometric analysis of immunoblot data. Cell lysates (30 µg) from HT-29 cells untreated or treated for indicated times with TFF3 (2.5 µM) were subjected to SDS-PAGE and transferred onto membranes. The immunoblotting was performed as in Fig. 5. Data are means ± SE of 3 determinations. **P < 0.005 vs. 0 h. ***P < 0.001 vs. 0 h.

 
It has been shown that TFF3 activates ERK kinase in intestinal epithelial cells (49). To examine the signal mechanisms by which TFF3 upregulates the expression of Twist protein, HT-29 cells were pretreated with U126 (10 µM, a potent ERK kinase inhibitor) for 60 min and followed by treatment with TFF3 (2.5 µM) for 4 and 24 h, respectively. As shown in Fig. 8, TFF3 increased the expression of Twist protein in intestinal epithelial cells. Pretreatment of cells with U0126 resulted in blocking the effect of TFF3 on expression of Twist protein. In addition, we obtained similar results by using PD-98059, another potent ERK inhibitor (data not shown). Together, these data suggest that ERK kinase mediates TFF3 action.



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 8. U0126, a potent ERK inhibitor, blocks TFF3 effect of increasing Twist protein in IECs. Cell lysates (30 µg) from IEC-18 cells untreated or treated with indicated stimulators were subjected to SDS-PAGE and transferred onto membranes. The membranes were subjected to Western blot and densitometric analysis as in Fig. 5. Results are means ± SE of 3 independent experiments. *P < 0.05, significantly different from untreated.

 
Twist plays a role in blocking IL-8 production in TFF3-stimulated intestinal epithelial cells. To eliminate Twist protein from HT-29 cells, we silenced Twist expression using a siRNA strategy. As demonstrated in Fig. 9A, treatment with siRNA for Twist resulted in the attenuation of Twist protein expression in intestinal epithelial cells within 5 days. To examine whether Twist protein modulates IL-8 expression in TFF3-stimulated cells, HT-29 cells were transfected with Twist siRNA for 4 days and treated with TFF3 (2.5 µM) for 18 h. Conditioned medium was then collected for IL-8 assay. As shown in Fig. 9B, HT-29 cells constitutively secrete IL-8 protein. The basal level of IL-8 in cells with silenced Twist was not changed compared with the control group, suggesting that constitutive IL-8 expression in HT-29 cells is not modulated by Twist protein. In contrast, TFF3 markedly induced IL-8 secretion in HT-29 cells with silenced Twist, indicating endogenous Twist protein plays a role in balancing IL-8 expression during transient NF-{kappa}B activation in intestinal epithelial cells by TFF3.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 9. RNAi reduces Twist expression, which results in induction of IL-8 expression in TFF3-stimulated IECs. A: reduction of endogenous Twist gene expression using small interfering RNA (siRNA). HT-29 cells were transfected with siRNA against Twist, as described in MATERIALS AND METHODS. Five days later, cell lysates were immunoblotted for Twist and GAPDH, respectively. Data are representative of 3 separate experiments. siTwist, siRNA for Twist gene; siNS, nonspecific siRNA. B: reduction of Twist expression results in induction of IL-8 in TFF3-treated IECs. HT-29 cells were treated with siTwist, siNS, or no siRNA, and, 4 days later, stimulated with TFF3 (2.5 µM) for 18 h. Conditioned medium from untreated or treated cells were subjected to measurement of IL-8 with ELISA assay, as described in MATERIALS AND METHODS. Results are means ± SE of 3 independent experiments. *P < 0.05, significantly different from control.

 

    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
A growing body of evidence suggests that transiently activated NF-{kappa}B in noninflammatory states and persistently activated NF-{kappa}B during inflammation play different pathophysiological roles in vivo. During the initial phase of inflammation, proinflammatory cytokines and mediators induce prolonged NF-{kappa}B activation in various inflammatory cells and endothelium. The activated NF-{kappa}B further upregulates the expression of several proinflammatory molecules, such as endothelial cell adhesion molecules and macrophage inflammatory protein-2, which triggers neutrophilic infiltration and tissue injury (1, 27, 34). Thus persistent NF-{kappa}B activation during the early phase of inflammation amplifies inflammatory response in vivo.

In contrast, transient activation of NF-{kappa}B before inflammatory stimulation results in the anti-inflammatory response. For example, several investigators (41, 54, 56) have found that transient activation of NF-{kappa}B is required for the heart to tolerate ischemia-reperfusion-induced myocardial stunning and myocardial infarction. Pretreatment of rats with low-molecular-weight hyaluronic acid induces hepatoprotection against inflammatory insults via transient activation of NF-{kappa}B (52). In the intestine, preconditioning with lipopolysaccharide results in transient activation of NF-{kappa}B and induces protective mechanisms against intestinal dysfunction (40).

In the present study, we have demonstrated that TFF3-induced NF-{kappa}B activation is a transient event. The transient activation of NF-{kappa}B by TFF3 is followed by induction of Twist protein, a NF-{kappa}B-associated negative regulatory molecule for the NF-{kappa}B pathway. Previous studies have shown that Twist interacts with NF-{kappa}B (43). It represses NF-{kappa}B activity and attenuates the inflammatory response via suppression of NF-{kappa}B activity (43). We showed that silencing expression of Twist in TFF3-treated cells results in the induction of IL-8, a NF-{kappa}B-regulated proinflammatory cytokine. Thus TFF3-induced transient activating NF-{kappa}B is associated with strengthening of the negative regulatory loop of NF-{kappa}B, which inhibits proinflammatory cytokine expression in intestinal epithelial cells and protects against inflammation of the GI mucosa.

Intestinal epithelial cells play a unique role in the GI inflammation through their ability to release proinflammatory cytokines such as IL-1{beta} and IL-8. Previously, we and others have shown that inflammatory mediators induce NF-{kappa}B activation in the intestine (14, 15, 22, 48). The activated NF-{kappa}B further upregulates the expression of several proinflammatory molecules, such as endothelial cell adhesion molecules and macrophage inflammatory protein-2, which result in neutrophilic infiltration and mucosal injury (1, 27, 34). NF-{kappa}B is controlled by a negative control loop. However, it is not clear whether the loop is regulated during the inflammation. Herein we report for the first time that Twist protein, a novel molecule in the loop, is present in intestinal epithelial cells in vivo. TNF induces marked degradation of Twist protein in intestinal epithelial cells by a proteasome-dependent mechanism. The effect is associated with TNF-induced NF-{kappa}B activity in the cells, which suggests that 1) cytokines regulate the expression of molecules in the loop and 2) reduction of Twist protein by TNF may result in maintenance of NF-{kappa}B activity. Persistent activation of NF-{kappa}B causes prolonged expression of genes, including both induction of and activation by NF-{kappa}B.

Previous studies (37, 51, 53) have shown that TFF3 is expressed in goblet cells and secreted onto intestinal lumen in normal circumstances. It targets intestinal epithelial cells. In contrast to TNF, TFF3 induces upregulation of Twist in intestinal epithelial cells. Thus TFF3 probably plays an important role in maintaining Twist protein in intestinal epithelial cells, which may contribute to downregulation of inflammation in vivo.

The physiological function of Twist in intestinal epithelial cells is not clear. Previously, Twist has been found to play an important role in negative regulation of NF-{kappa}B in vivo (43). Thus we hypothesize that endogenous Twist in intestinal epithelial cells is involved in controlling proinflammatory cytokine expression during inflammation. This hypothesis is further supported by our observation that TFF3 induces IL-8 production after elimination of Twist protein from intestinal epithelial cells. Furthermore, because TNF induces degradation of Twist in intestinal epithelial cells, which is associated with prolonged NF-{kappa}B activation, prevention of cytokine-induced downregulation of Twist protein may be a novel strategy for blocking inflammation in the GI tract.

In addition to participation in negative regulation of the NF-{kappa}B signaling pathway, induction of Twist has been shown to play an essential role in the prevention of cells from undergoing apoptosis (30). Interestingly, we (8) and others (50) showed that TFF3 protects intestinal epithelial cells against apoptosis. Taken together, TFF3-induced Twist protein may mediate the antiapoptotic effect of TFF3 in intestinal epithelial cells.

Previously, we and others have demonstrated that intestinal epithelial cells are the target of TFF3 (51). TFF3 binds to intestinal epithelial cells (11, 46, 47). In response to TFF3 stimulation, intestinal epithelial cells release nitric oxide and prostaglandins (45, 47). TFF3 activates several intracellular molecules such as NF-{kappa}B and ERK in intestinal epithelial cells (8, 49). In the present study, we found that TFF3 enhances Twist protein levels in intestinal epithelial cells. We further showed that the selective inhibitor of ERK kinase attenuates the effect of TFF3 on the upregulation of Twist protein, suggesting that TFF3 activates a distinctive signal pathway involved in the modulation of Twist protein. These observations indicate that multiple intracellular regulatory molecules, including ERK, I{kappa}B{alpha}, Twist, and NF-{kappa}B complex may participate to mediate the effect of TFF3. Dissection of the distinctive signal pathway linking these molecules is the subject of our ongoing research.

In summary, we found that TFF3 activates intestinal epithelial NF-{kappa}B by a mechanism distinct from TNF. We demonstrated for the first time that intestinal epithelial cells constitutively express Twist protein, a novel negative regulator of the NF-{kappa}B pathway. We showed that TNF, which induces prolonged NF-{kappa}B activation, induces degradation of Twist protein in intestinal epithelial cells. The TNF effect is mediated by the proteasome activity. In contrast, TFF3, which activates NF-{kappa}B in a transient event, upregulates Twist protein in intestinal epithelial cells. The effect of TFF3 is mediated by endogenous ERK activity. In addition, we showed that Twist protein plays an important role in silencing IL-8 production in NF-{kappa}B- activated intestinal epithelial cells. Further understanding of these mechanisms will provide new insights into the controlling process involved in the activation of NF-{kappa}B in inflammation and may lead to the development of a new pharmaceutical to block GI inflammation.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This work was supported in part by National Institute of Diabetes and Digestive and Kidney Diseases Grant R01 DK-064240, a grant from the Crohn’s and Colitis Foundation of America, and an Eloise and Warren Batts Investigator Award (all to X.-D. Tan).


    ACKNOWLEDGMENTS
 
We thank Yu Lu for technical assistance, and Adrienne G. Woodworth and Leah M. Edmonson for preparation of the manuscript. Y.-Q. Zhu is a visiting scholar from China Medical University, Shenyang, China.


    FOOTNOTES
 

Address for reprint requests and other correspondence: X.-D. Tan, Molecular and Cellular Pathobiology Program, Children’s Memorial Research Center, Children’s Memorial Hospital, 2300 Children’s Plaza, Box 217, Chicago, IL 60614 (e-mail: xtan{at}northwestern.edu) or Y.-Q. Zhu (e-mail: yaqin-zhu{at}northwestern.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
1. Ajuebor MN and Swain MG. Role of chemokines and chemokine receptors in the gastrointestinal tract. Immunology 105: 137–143, 2002.[CrossRef][ISI][Medline]

2. Alison MR, Chinery R, Poulsom R, Ashwood P, Longcroft JM, and Wright NA. Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach. J Pathol 175: 405–414, 1995.[CrossRef][ISI][Medline]

3. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelerie F, Thomas D, and Hay RT. Inducible nuclear expression of newly synthesized I{kappa}B{alpha} negatively regulates DNA-binding and transcriptional activities of NF-{kappa}B. Mol Cell Biol 15: 2689–2696, 1995.[Abstract]

4. Auphan N, DiDonato JA, Rosette C, Helmberg A, and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-{kappa}B activity through induction of I kappa B synthesis. Science 270: 286–290, 1995.[Abstract]

5. Babyatsky MW, deBeaumont M, Thim L, and Podolsky DK. Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 110: 489–497, 1996.[CrossRef][ISI][Medline]

6. Brasier AR, Lu M, Hai T, Lu Y, and Boldogh I. NF-{kappa}B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-{kappa}B1 residence. J Biol Chem 276: 32080–32093, 2001.[Abstract/Free Full Text]

7. Carlson DL, White DJ, Maass DL, Nguyen RC, Giroir B, and Horton JW. I{kappa}B overexpression in cardiomyocytes prevents NF-{kappa}B translocation and provides cardioprotection in trauma. Am J Physiol Heart Circ Physiol 284: H804–H814, 2003.[Abstract/Free Full Text]

8. Chen YH, Lu Y, De Plaen IG, Wang LY, and Tan XD. Transcription factor NF-{kappa}B signals antianoikic function of trefoil factor 3 on intestinal epithelial cells. Biochem Biophys Res Commun 274: 576–582, 2000.[CrossRef][ISI][Medline]

9. Chen ZF and Behringer RR. Twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 9: 686–699, 1995.[Abstract]

10. Chiao PJ, Miyamoto S, and Verma IM. Autoregulation of I{kappa}B{alpha} activity. Proc Natl Acad Sci USA 91: 28–32, 1994.[Abstract/Free Full Text]

11. Chinery R and Cox HM. Immunoprecipitation and characterization of a binding protein specific for the peptide, intestinal trefoil factor. Peptides 16: 749–755, 1995.[CrossRef][ISI][Medline]

12. Conte E, Bonaiuto C, Nesci C, Crimi N, Vancheri C, and Messina A. Nuclear factor-{kappa}B activation in human monocytes stimulated with lipopolysaccharide is inhibited by fibroblast conditioned medium and exogenous PGE2. FEBS Lett 400: 315–318, 1997.[CrossRef][ISI][Medline]

13. D’Acquisto F, Sautebin L, Iuvone T, Di Rosa M, and Carnuccio R. Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-{kappa}B activation in J774 macrophages. FEBS Lett 440: 76–80, 1998.[CrossRef][ISI][Medline]

14. De Plaen IG, Tan XD, Chang H, Qu XW, Liu QP, and Hsueh W. Intestinal NF-{kappa}B is activated, mainly as p50 homodimers, by platelet-activating factor. Biochim Biophys Acta 1392: 185–192, 1998.[ISI][Medline]

15. De Plaen IG, Tan XD, Chang H, Wang L, Remick DG, and Hsueh W. Lipopolysaccharide activates nuclear factor {kappa}B in rat intestine: role of endogenous platelet-activating factor and tumour necrosis factor. Br J Pharmacol 129: 307–314, 2000.[CrossRef][ISI][Medline]

16. Dignass A, Lynch-Devaney K, Kindon H, Thim L, and Podolsky DK. Trefoil peptides promote epithelial migration through a transforming growth factor {beta}-independent pathway. J Clin Invest 94: 376–383, 1994.[ISI][Medline]

17. Hoffmann W, Jagla W, and Wiede A. Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol 16: 319–334, 2001.[ISI][Medline]

18. Howe LR, Watanabe O, Leonard J, and Brown AM. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 63: 1906–1913, 2003.[Abstract/Free Full Text]

19. Hu X. Proteolytic signaling by TNF{alpha}: caspase activation and IkappaB degradation. Cytokine 21: 286–294, 2003.[CrossRef][ISI][Medline]

20. Hu X, Bryington M, Fisher AB, Liang X, Zhang X, Cui D, Datta I, and Zuckerman KS. Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest. J Biol Chem 277: 16528–16537, 2002.[Abstract/Free Full Text]

21. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA, and Peyron JF. Tyrosine phosphorylation of I{kappa}B-{alpha} activates NF-{kappa}B without proteolytic degradation of I{kappa}B-{alpha}. Cell 86: 787–798, 1996.[CrossRef][ISI][Medline]

22. Jobin C, Panja A, Hellerbrand C, Iimuro Y, Didonato J, Brenner DA, and Sartor RB. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol 160: 410–418, 1998.[Abstract/Free Full Text]

23. Karin M and Lin A. NF-{kappa}B at the crossroads of life and death. Nat Immun 3: 221–227, 2002.[CrossRef][ISI]

24. Kindon H, Pothoulakis C, Thim L, Lynch-Devaney K, and Podolsky DK. Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology 109: 516–523, 1995.[CrossRef][ISI][Medline]

25. Laherty CD, Hu HM, Opipari AW, Wang F, and Dixit VM. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 267: 24157–24160, 1992.[Abstract/Free Full Text]

26. Laherty CD, Perkins ND, and Dixit VM. Human T cell leukemia virus type I Tax and phorbol 12-myristate 13- acetate induce expression of the A20 zinc finger protein by distinct mechanisms involving nuclear factor kappa B. J Biol Chem 268: 5032–5039, 1993.[Abstract/Free Full Text]

27. Laskowski I, Pratschke J, Wilhelm MJ, Gasser M, and Tilney NL. Molecular and cellular events associated with ischemia/reperfusion injury. Ann Transplant 5: 29–35, 2000.[Medline]

28. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, and Ma A. Failure to regulate TNF-induced NF-{kappa}B and cell death responses in A20-deficient mice. Science 289: 2350–2354, 2000.[Abstract/Free Full Text]

29. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, Russell SW, and Murphy WJ. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci USA 90: 9730–9734, 1993.[Abstract/Free Full Text]

30. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, and Hannon GJ. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13: 2207–2217, 1999.[Abstract/Free Full Text]

31. Matsuoka Y, Pascall JC, and Brown KD. Quantitative analysis reveals differential expression of mucin (MUC2) and intestinal trefoil factor mRNAs along the longitudinal axis of rat intestine. Biochim Biophys Acta 1489: 336–344, 1999.[ISI][Medline]

32. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, and Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc Natl Acad Sci USA 96: 10403–10408, 1999.[Abstract/Free Full Text]

33. Moro F, Levenez F, Durual S, Plaisancie P, Thim L, Giraud AS, and Cuber J. Secretion of the trefoil factor TFF3 from the isolated vascularly perfused rat colon. Regul Pept 101: 35–41, 2001.[CrossRef][ISI][Medline]

34. Olson TS and Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 283: R7–R28, 2002.[Abstract/Free Full Text]

35. Podolsky DK. Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. J Gastroenterol 35, Suppl 12: 69–74, 2000.[ISI][Medline]

36. Sands BE, Ogata H, Lynch-Devaney K, deBeaumont M, Ezzell RM, and Podolsky DK. Molecular cloning of the rat intestinal trefoil factor gene. Characterization of an intestinal goblet cell-associated promoter. J Biol Chem 270: 9353–9361, 1995.[Abstract/Free Full Text]

37. Sands BE and Podolsky DK. The trefoil peptide family. Annu Rev Physiol 58: 253–273, 1996.[CrossRef][ISI][Medline]

38. Scheinman RI, Cogswell PC, Lofquist AK, and Baldwin AS Jr. Role of transcriptional activation of I{kappa}B{alpha} in mediation of immunosuppression by glucocorticoids. Science 283–286, 1995.

39. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, and Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272: 601–608, 1997.[Abstract/Free Full Text]

40. Schwarz NT, Engel B, Eskandari MK, Kalff JC, Grandis JR, and Bauer AJ. Lipopolysaccharide preconditioning and cross-tolerance: the induction of protective mechanisms for rat intestinal ileus. Gastroenterology 123: 586–598, 2002.[CrossRef][ISI][Medline]

41. Shinmura K, Xuan YT, Tang XL, Kodani E, Han H, Zhu Y, and Bolli R. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 90: 602–608, 2002.[Medline]

42. Sosic D and Olson EN. A new twist on Twist–modulation of the NF-{kappa}B pathway. Cell Cycle 2: 76–78, 2003.[Medline]

43. Sosic D, Richardson JA, Yu K, Ornitz DM, and Olson EN. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-{kappa}B activity. Cell 112: 169–180, 2003.[CrossRef][ISI][Medline]

44. Sun SC, Ganchi PA, Ballard DW, and Greene WC. NF-kappa B controls expression of inhibitor I{kappa}B{alpha}: evidence for an inducible autoregulatory pathway. Science 259: 1912–1915, 1993.[ISI][Medline]

45. Tan XD, Chen Y, Liu Q, Gonzalez-Crussi F, and Liu X. Prostanoids mediate the protective effect of trefoil factor 3 in oxidant-induced intestinal epithelial cell injury: role of cyclooxygenase-2. J Cell Sci 113: 2149–2155, 2000.[Abstract/Free Full Text]

46. Tan XD, Hsueh W, Chang H, Wei KR, and Gonzalez-Crussi F. Characterization of a putative receptor for intestinal trefoil factor in rat small intestine: identification by in situ binding and ligand blotting. Biochem Biophys Res Commun 237: 673–677, 1997.[CrossRef][ISI][Medline]

47. Tan XD, Liu QP, Hsueh W, Chen YH, Chang H, and Gonzalez-Crussi F. Intestinal trefoil factor binds to intestinal epithelial cells and induces nitric oxide production: priming and enhancing effects of mucin. Biochem J 338: 745–751, 1999.[CrossRef][ISI][Medline]

48. Tan XD, Sun X, Gonzalez-Crussi FX, Gonzalez-Crussi F, and Hsueh W. PAF and TNF increase the precursor of NF-{kappa}B p50 mRNA in mouse intestine: quantitative analysis by competitive PCR. Biochim Biophys Acta 1215: 157–162, 1994.[ISI][Medline]

49. Taupin D, Wu DC, Jeon WK, Devaney K, Wang TC, and Podolsky DK. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J Clin Invest 103: R31–R38, 1999.[ISI][Medline]

50. Taupin DR, Kinoshita K, and Podolsky DK. Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci USA 97: 799–804, 2000.[Abstract/Free Full Text]

51. Thim L. Trefoil peptides: from structure to function. Cell Mol Life Sci 53: 888–903, 1997.[CrossRef][ISI][Medline]

52. Wolf D, Schumann J, Koerber K, Kiemer AK, Vollmar AM, Sass G, Papadopoulos T, Bang R, Klein SD, Brune B, and Tiegs G. Low-molecular-weight hyaluronic acid induces nuclear factor-{kappa}B-dependent resistance against tumor necrosis factor-{alpha}-mediated liver injury in mice. Hepatology 34: 535–547, 2001.[CrossRef][ISI][Medline]

53. Wright NA, Hoffmann W, Otto WR, Rio MC, and Thim L. Rolling in the clover: trefoil factor family (TFF)-domain peptides, cell migration and cancer. FEBS Lett 408: 121–123, 1997.[CrossRef][ISI][Medline]

54. Xuan YT, Tang XL, Banerjee S, Takano H, Li RC, Han H, Qiu Y, Li JJ, and Bolli R. Nuclear factor-{kappa}B plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 84: 1095–1109, 1999.[Abstract/Free Full Text]

55. Yamamoto Y and Gaynor RB. Role of the NF-{kappa}B pathway in the pathogenesis of human disease states. Curr Mol Med 1: 287–296, 2001.[CrossRef][Medline]

56. Zhao TC, Taher MM, Valerie KC, and Kukreja RC. p38 Triggers late preconditioning elicited by anisomycin in heart: involvement of NF-{kappa}B and iNOS. Circ Res 89: 915–922, 2001.[Medline]

57. Zhu YQ, Lu Y, and Tan XD. Monochloramine induces reorganization of nuclear speckles and phosphorylation of SRp30 in human colonic epithelial cells: role of protein kinase C. Am J Physiol Cell Physiol 285: C1294–C1303, 2003.[Abstract/Free Full Text]